Abstract

The clinicopathologic relevance and prognostic value of tumor deposits in colorectal cancer has been widely demonstrated. However, there are still debates in the prognostic value of tumor deposits and the applicability of N1c category in rectal cancer with preoperative radiotherapy. In this study, rectal cancer with preoperative radiotherapy followed by resection of primary tumors registered in Surveillance, Epidemiology and End Results (SEER) database from 2010-2012 were analyzed. There were 4,813 cases eligible for this study, and tumor deposits were found in 514 (10.7%) cases. The presence of tumor deposits was significantly associated with some aggressive characteristics, including poorer tumor differentiation, more advanced ypT category, ypN category and ypTNM stage, distant metastasis, elevated carcinoembryonic antigen, higher positive rates of circumferential resection margin and perineural invasion (all P < = 0.001). Tumor deposit was also an independent negative prognostic factor for cancer-specific survival in rectal cancer with preoperative radiotherapy (adjusted HR and 95% CI: 2.25 (1.51 – 3.35)). N1c category had significant worse survival compared with N0 category (adjusted HR and 95% CI: 2.41 (1.24 – 4.69)). In conclusion, tumor deposit was a significant and independent prognostic factor, and the N1c category by the 7th edition of AJCC/TNM staging system was applicable in rectal cancer with preoperative radiotherapy.

Highlights

  • Rectal cancer is one of the most common malignancies of the digestive system

  • tumor deposits (TDs) was present in tumors with more aggressive features, including poorer differentiation, distant metastasis, higher carcinoembryonic antigen (CEA) level, higher rates of circumferential resection margin (CRM) involvement and perineural invasion

  • Since regional lymph nodes negative cases with TDs was classified as N1c in the 7th AJCC/TNM staging system, our analysis proved the rationale of N1c category in rectal cancer with preoperative radiotherapy

Read more

Summary

Introduction

Rectal cancer is one of the most common malignancies of the digestive system. It ranks near the top of cancer incidence and cause specific death worldwide [1,2,3]. Surgery is the only curable treatment for early stage cases [4]. Some details remain to be explored, preoperative chemoradiotherapy has become the standard treatment strategy for locally advanced rectal cancer [5,6,7,8,9,10]. Adjuvant chemotherapy does not significantly reduce recurrence, improve diseasefree survival (DFS) or overall survival (OS) according to recent studies [11, 12]. Identification of significant prognostic factors helps to determine subgroups with high risk, who may benefit from subsequent systemic chemotherapy

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call